论文部分内容阅读
AG331,化学名称为N6-[4-(磺酰吗啉基)苄基]-N6-甲基-2,6-二氨基苯并[cd]吲哚葡糖醛酸盐,是根据胸腺嘧啶核苷酸合成酶(TS)三维结构的活性部位设计出的新型的TS抑制剂。AG331期临床研究的目的是通过单剂量和多剂量给药确定其全身和局部耐受性并研究其药代动力学特点。受试病人为1
AG331 with the chemical name N6- [4- (sulfonylmorpholino) benzyl] -N6-methyl-2,6-diaminobenz [cd] indole glucuronate, (TS) three-dimensional structure of the active site designed a new type of TS inhibitors. The purpose of the AG331 phase of clinical studies was to determine systemic and local tolerability and to study its pharmacokinetic characteristics by single and multiple dose administrations. The patient was 1